Lilly invests further in Irish manufacturing
This article was originally published in Scrip
Ireland's export market, which anticipates taking a significant hit in the coming year as a number of pharmaceuticals manufactured on its shores come off patent, has had some good news. Lilly, which already has a significant manufacturing presence in the country, announced this week that it intends to invest €330 million in building a brand new facility at its Kinsale, Cork site.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.